Role of novel hormonal therapies in the management of non‑metastatic castration‑resistant prostate cancer:: a literature‑based meta‑analysis of randomized trials

• G. Roviello ^[1] ; M. R. Gatta Michelet ^[1] ; A. Angelo ^[2] ; S. Nobili ^[1] ; E. Mini ^[1]
  1. [1] University of Florence

     University of Florence

     Firenze, Italia

     
  2. [2] University of Bath

     University of Bath

     Reino Unido

     
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 22, Nº. 7, 2020, págs. 1033-1039
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • ackgroundNovel hormonal therapies have been recently investigated in non-metastatic castration-resistant prostate cancer (CRPC). We performed a meta-analysis to assess the efficacy and safety of novel hormonal therapies in non-metastatic CRPC.Materials and methodsThe primary outcome was metastasis-free survival (MFS). The secondary endpoints were overall survival (OS), time to PSA progression and safety. We planned a subgroup analysis according to the PSA doubling time (> 6 vs < 6 months), Eastern Cooperative Oncology Group (ECOG) performance status (1 vs 0) and concomitant use of bone-targeting agent (yes vs no).ResultsPooled analysis of novel hormonal therapies revealed significantly increased MFS compared with placebo (hazard ratio (HR): HR = 0.32, 95% CI 0.25–0.41; p < 0.00001). The subgroup analysis showed a statistically significant MFS advan-tage in favour of men with the lower ECOG performance status. Other secondary endpoints favoured the novel hormonal therapies. The relative risk (RR) of grade ≥ 3 adverse events and ≥ 3 hypertension was 1.31 and 1.39, respectively.ConclusionsThis study confirmed the efficacy and safety of the novel hormonal therapies in non-metastatic CRPC.